You are here

CONTROLLED HEAT-AIDED TRANSDERMAL DRUG DELIVERY:FENTANYL

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: PHS2001-2
Agency Tracking Number: 1R41GM060886-01A1
Amount: $142,248.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
350 W 800 N, STE 320 SALT LAKE CITY, UT 84108
SALT LAKE CITY, UT 84108
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JIE ZHANG
 (801) 581-6393
 JZHANG@ANESTH.MED.UTAH.EDU
Business Contact
Phone: (801) 350-0202
Email: LRIGBY@ZARS.COM
Research Institution
N/A
Abstract

DESCRIPTION (Adapted from the application): The investigators believe the
fentanyl transdermal patch currently available has several limitations
including the requirement of a long time to reach peak effect and that it
cannot be used to treat breakthrough pain (short-lasting episodes of increased
pain). ZARs' preliminary data, using its patented controlled, heat-aided drug
delivery (CHADD) technology has demonstrated an ability to significantly enhance the
dermal absorption of fentanyl from commercially available fentanyl skin
patches. The aim of the proposed research is to develop a CHADD system that can
significantly shorten the time it takes a fentanyl skin patch to reach peak
effect and to prove the concept that CHADD can be utilized to produce a rapid
bolus of fentanyl from skin patches, sufficient to treat breakthrough pain.
PROPOSED COMMERCIAL APPLICATION:
The commercial product will be prescribed by doctors for the treatment of both chronic
pain (including severe cancer-related pain) and breakthrough pain (short-lasting episodes
of increased pain).

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government